How much GHRP-6 do studies give, and how is a vial mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds GHRP-6 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    A DailyMed search found no US label for GHRP-6, and the one subcutaneous dose in the sources found comes from a retrospective review of records (Sigalos et al.), in which 14 of 105 hypogonadal men on testosterone met its inclusion criteria: 100 mcg each of GHRP-6, GHRP-2 and sermorelin, injected subcutaneously three times daily.1

    The guide's example

    100 mcg of GHRP-6 from a 5 mg vial mixed with 2 mL is 4 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water
    5 mg5 mg/mL: 100 mcg is 2 units2.5 mg/mL: 100 mcg is 4 units

    Mixing and syringe units

    Searches of DailyMed, ClinicalTrials.gov and PubMed found no label or trial giving GHRP-6 vial strengths or concentrations. They also found no label or leaflet saying which water to use or how much. The conversion therefore has no sourced concentration to start from, so the table is arithmetic, not a product.

    As a worked example, a 5 mg vial mixed with 2 mL is 2.5 mg/mL, so 100 mcg, the amount of each compound in the Sigalos et al. review,1 is 4 units on a U-100 syringe.

    100 mcg of GHRP-6 from a 5 mg vial mixed with 2 mL is 4 units on a U-100 syringe.

    The calculator is at the top of the page

    Doses and schedules in human studies

    In the sources found, GHRP-6 doses are mostly per kilogram of body weight and mostly intravenous or oral; only one source gives a subcutaneous dose, and it is a combination of three compounds.

    StudyRoute, dose and schedulePeopleLength
    Sigalos et al., retrospective review1Subcutaneous, 100 mcg of each compound, three times daily, with GHRP-2 and sermorelin14 of 105 hypogonadal men on testosterone therapy whose records were reviewed met its inclusion criteriaMean (SD) 134 (88) days
    Cabrales et al.2Single intravenous bolus, 100, 200 and 400 μg/kg of body weightNine male healthy volunteersSingle dose
    Jaffe et al.3Intravenous, 1 microgram/kg loading bolus then 1 microgram/kg.h, compared with a normal saline infusionNine healthy young men34-h infusion
    Ghigo et al.4By mouth, 300 micrograms/kg, tested before and after 4 days of treatment with the hexapeptide given twice dailySeven normal elderly women aged 65-82 years4 days of treatment
    Cordido et al.5Intravenous, 100 micrograms of GHRP-6, alone or with GHRH at 100 micrograms19 obese subjectsNot stated
    Frieboes et al.6Intravenous, repetitive boluses of 4 x 50 micrograms, compared with placeboNormal men, number not givenNot stated; sleep EEG recorded 23.00 to 07.00 h

    Milligram has no logged GHRP-6 dose or schedule shares at its reporting floor.

    Storage and status

    Searches of DailyMed, ClinicalTrials.gov and PubMed found no storage condition for GHRP-6 before or after mixing. A 2026 narrative review says no long term safety data are available for GHRP-6 and grades its evidence as phase I and small mechanistic human studies (acute GH/PRL/ACTH responses), with no controlled efficacy trials.7 FDA lists GHRP-6 (503B, September 29, 2023) among substances in compounding that may present significant safety risks, saying compounded drugs containing it may pose risk for immunogenicity for certain routes of administration.8

    Frequently asked questions

    Is GHRP-6 given with GHRH?

    In 18 normal men (Bowers et al.), submaximal intravenous bolus doses of 0.1 and 0.3 microgram/kg GHRP plus 1 microgram/kg GHRH stimulated GH release synergistically.9 A diagnostic study (Popovic et al.) gave GHRH 1 microg per kg plus GHRP-6 1 microg per kg intravenously, once at 0 min, to 125 adult patients with organic pituitary disease and 125 healthy individuals, with blood sampled over the next 120 min.10 The Sigalos et al. review in the table above combined GHRP-6 with the GHRH agonist sermorelin and with GHRP-2.1

    Does GHRP-6 raise IGF-1?

    In the infusion study by Jaffe et al. in nine healthy young men, plasma IGF-I increased from 252 +/- 23 to 312 +/- 23 micrograms/L with the 34-h GHRP infusion in the table above; on day 2 the protocol also gave iv boluses of TRH, GHRH and GHRP, and no IGF-I figure is given for the saline infusion.3 In the Sigalos et al. review of 14 hypogonadal men on testosterone who met its strict inclusion criteria after compliance with therapy was assessed, mean (SD) IGF-1 rose from 159.5 (26.7) to 239.0 (54.6) ng/mL over a mean (SD) 134 (88) days of GHRP-6, GHRP-2 and sermorelin.1 In the Ghigo study, IGF-I levels were not increased significantly after four days of oral GHRP-6 twice daily in seven elderly women (77.1 +/- 8.4 vs 84.1 +/- 12.2 micrograms/l).4

    By which routes has GHRP-6 been given?

    A trial in 13 children with normal short stature (Bellone et al.) states that GHRP-6 has potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man.11 In a comparison of routes against placebo conditions in normal young men, number not given (Frieboes et al.), 300 microg/kg GHRP-6 in enteric-coated capsules by mouth at 21.00 h left GH, ACTH and cortisol unchanged, 30 microg/kg sublingually at 22.45 h showed only a trend toward an increase in GH in the first half of the night, and 30 microg/kg intranasally at 22.45 h prompted a significant increase in GH concentration during the total night; the authors say the effects depend upon dosage, duration and route of administration.12

    References

    1. PMC. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. 2017. pmc.ncbi.nlm.nih.gov
    2. PubMed. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. 2013. pubmed.ncbi.nlm.nih.gov
    3. PubMed. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. 1993. pubmed.ncbi.nlm.nih.gov
    4. PubMed. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. 1994. pubmed.ncbi.nlm.nih.gov
    5. PubMed. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. 1993. pubmed.ncbi.nlm.nih.gov
    6. PubMed. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. 1995. pubmed.ncbi.nlm.nih.gov
    7. PMC. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
    8. FDA. Substances in Compounding that May Present Significant Safety Risks. 2026. fda.gov
    9. PubMed. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. 1990. pubmed.ncbi.nlm.nih.gov
    10. PubMed. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. 2000. pubmed.ncbi.nlm.nih.gov
    11. PubMed. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. 1995. pubmed.ncbi.nlm.nih.gov
    12. PubMed. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. 1999. pubmed.ncbi.nlm.nih.gov